Overexpression of CD59 inhibits apoptosis of T-acute lymphoblastic leukemia via AKT/Notch1 signaling pathway

Abstract

BackgroundT-acute lymphoblastic leukemia (T-ALL) was a hematological malignancy characterized by the accumulation of immature T cells in bone marrow and peripheral blood. In this study, we tried to explore the physiological role of CD59 in T-ALL.MethodsIn this study, we collected the bone marrow samples from 17 T-ALL patients and 38 healthy participants to find differences in CD59 expression patterns. Then, CD59 was over-expressed in T-ALL cell line Jurkat, and its biological functions were detected. In addition, in order to understand the active site of CD59, the Trp40 was mutated. Further, we constructed a mouse model by transplanting Jurkat cells into the nude mice to verify the function of CD59 in vitro. At last, mechanism studies were performed by western blot.ResultsWe found that the proportion of T lymphocytes expressing CD59 in bone marrow of T-ALL patients was significantly higher than that of healthy individuals. Then, we found that the overexpression of CD59 in Jurkat cells was beneficial to the cell survival by inhibiting apoptosis and promoting IL-2 secretion. In this process, Trp40 of CD59 was a key functional site. Further, the high expression of CD59 inhibited apoptosis of bone marrow and peripheral blood cells, and promoted IL-2 secretion in mouse model. At last, mechanism studies showed that the activation of AKT, STAT5 and Notch1 signaling pathways in Jurkat cells, may be involved in the regulation of apoptosis by CD59; and mutation in the Trp40 affect the interaction of CD59 with these signaling pathways.ConclusionsIn conclusion, CD59 inhibited apoptosis of T-ALL by regulating AKT/Notch1 signaling pathway, providing a new perspective for the treatment of T-ALL.Electronic supplementary materialThe online version of this article (10.1186/s12935-018-0714-9) contains supplementary material, which is available to authorized users.

Coenzyme Q10 attenuates rat hepatocarcinogenesis via the reduction of CD59 expression and phospholipase D activity

“…The expression of CD59 was increased in HCC on both of mRNA and protein levels. This was also reported in different cancer tissues because of its great role in enhancing tumour growth . The level of serum CD59 was also increased in HCC when compared with control.…”

Complement Membrane Attack Complex

“…MAC has been found to activate pathways in cancer cells that inhibit death signals and induce mechanisms of evasion of complementdependent cytotoxicity, such as blocking MAC assembly and increasing MAC elimination from the cell surface. 65 Increased presentation of CD59 on leukemic cancer cells reduces effectiveness of rituximab by inhibiting apoptosis 66,67 and on tumor cells leads to increased tumor progression in a model of neuroblastoma. 68 Cancer cells activate protective pathways, including CD46, CD55, and CD59, to inhibit complement activation to reduce number of MAC inserted to counteract death signals.…”

The expression and clinical significance of CD59 and FLAER in Chinese adult AML patients

“…Indeed, we discovered a significant reduction in CD59 and FLAER expression in AML, impairing AML pathophysiology. Recent studies revealed that proportion of T lymphocytes expressing CD59 was significantly higher in the bone marrow of T-ALL patients than in healthy individuals, 29 but the molecular mechanism by which this predicts poor prognosis and disease progression remains unclear.…”